Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

RBC Capital analyst Luca Issi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of $95.00. The ...

Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on Korro Bio (KRRO – Research Report) and keeping the price target at ...

Cambridge, USA-based Korro Bio has entered a collaboration with Denmark’s Novo Nordisk to advance the discovery and ...

CAMBRIDGE, Mass. - Korro Bio, Inc. (NASDAQ:KRRO), a biopharmaceutical company, has announced a strategic collaboration with global healthcare company Novo Nordisk (NYSE:NVO) to develop new genetic ...

Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

Korro Bio Inc. has established a collaboration with Novo Nordisk A/S to advance the discovery and development of new genetic medicines, initially to treat cardiometabolic diseases. The collaboration ...

CAMBRIDGE, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on ...

CAMBRIDGE, Mass. - Korro Bio, Inc. (NASDAQ:KRRO), a biopharmaceutical company, has announced a strategic collaboration with global healthcare company Novo Nordisk (NYSE:NVO) to develop new genetic ...

Sept. 16, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on RNA editing for both ...